secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2026-06-26T20:15:14+00:00
Accession:  0001193125-26-285498
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Atara CAO to depart July 17; Kevin Sarney appointed interim CFO
---------------------------------------------------------------

- Yanina Grant-Huerta, Chief Accounting Officer, notified on June 22 that employment ends July 17, 2026.
- Board appointed Kevin G. Sarney (CRCFO) as interim CFO effective June 26; he serves as principal financial and accounting officer.
- Sarney has over 25 years life science finance experience, previously at PwC and executive roles at public/private life science companies.
- Sarney paid through CRCFO consulting; company pays hourly rate; no direct compensation from company.
- Consulting agreement terminable on 30 days notice; Sarney enters standard indemnification.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000119312526285498/0001193125-26-285498-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000119312526285498/atra-20260622.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-285498

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer